EN DE
STOCK COMPARISON

Firm Capital Mortgage Invest vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Firm Capital Mortgage Invest (FC) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 17, 2026.

As of Aug 17, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Firm Capital Mortgage Invest trades at C$11.88 versus a fair value of C$13.26 (+12%), while Fredun Pharmaceuticals trades at ₹1,548 versus ₹2,019 (+30%).
Firm Capital Mortgage Invest
FC.TO · CAD · Financials
+12%
upside to fair value
undervalued
PriceC$11.88
Fair ValueC$13.26
Quality73/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+30%
upside to fair value
undervalued
Price₹1,548
Fair Value₹2,019
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Firm Capital Mortgage InvestFredun Pharmaceuticals
Valuation
12.3×P/E (TTM)25.2×
7.60×P/S (TTM)2.23×
0.76×P/B5.03×
8.9×EV/EBITDA15.5×
7.7%Dividend yield0.0%
C$0.94Dividend per share₹0.70
Profitability
85%Net margin5%
86%Operating margin12%
9%Return on equity16%
6%Return on assets9%
Growth
-2%Revenue growth (YoY)27%
15.6%Avg. growth/yr (3Y)32.2%
14.7%Avg. growth/yr (5Y)36.9%
Balance & size
0.32×Debt / equity0.20×
$322MMarket cap$149M
mixedGrowth qualityexpensive

Fredun Pharmaceuticals leads: 6 to 7 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Firm Capital Mortgage Investof which business quality 68 · market factors 61 Fredun Pharmaceuticalsof which business quality 35 · market factors 55
ProfitabilityMargins and returns on capital today
42
48
Quality GrowthAre margins and returns improving?
43
73
CashflowEarnings quality: real cash, not paper profit
88
5
Fin. StrengthBalance sheet, leverage, solvency risk
55
57
InvestmentDisciplined investing over empire-building
96
16
Low VolatilityCalm price path (market factor)
88
43
MomentumPrice trend over the last 3–12 months (market factor)
45
55
52W MomentumDistance to the 52-week high (market factor)
58
68
Net IssuanceBuybacks instead of dilution
100
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Firm Capital Mortgage Invest

DCF ModelsC$12.26
Earnings-BasedC$15.26
Dividend DiscountC$13.12
MultiplesC$14.73
Asset-BasedC$7.75
Growth DCFC$14.02
Economic ProfitC$10.04

3 of 11 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,783
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,614

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Firm Capital Mortgage Invest
Bear C$9.54Fair Value C$13.26Bull C$16.57
C$11.88 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,379Fair Value ₹2,019Bull ₹2,712
₹1,548 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Firm Capital Mortgage Invest · Financials

Quality score73 · Top 25%
Fair value upside+12% · above median

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+30% · Top 25%

Bottom line

As of Aug 17, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Firm Capital Mortgage Invest trades at C$11.88 versus a fair value of C$13.26 (+12%), while Fredun Pharmaceuticals trades at ₹1,548 versus ₹2,019 (+30%).

Firm Capital Mortgage Invest has the higher quality score (73/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.